RT Journal Article
T1 Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.
A1 de la Hera, Belén
A1 Urcelay, Elena
A1 Brassat, David
A1 Chan, Andrew
A1 Vidal-Jordana, Angela
A1 Salmen, Anke
A1 Villar, Luisa Maria
A1 Alvarez-Cermeño, José Carlos
A1 Izquierdo, Guillermo
A1 Fernández, Oscar
A1 Oliver, Begoña
A1 Saiz, Albert
A1 Ara, Jose Ramón
A1 Vigo, Ana G
A1 Arroyo, Rafael
A1 Meca, Virginia
A1 Malhotra, Sunny
A1 Fissolo, Nicolás
A1 Horga, Alejandro
A1 Montalban, Xavier
A1 Comabella, Manuel
K1 Alelos
K1 Anticuerpos monoclonales humanizados
K1 Antígenos de histocompatibilidad clase I
K1 Prueba de histocompatibilidad
K1 Esclerosis múltiple
AB OBJECTIVESWe aimed to investigate potential associations between human leukocyte antigen (HLA) class I and class II alleles and the development of anaphylactic/anaphylactoid reactions in patients with multiple sclerosis (MS) treated with natalizumab.METHODSHLA class I and II genotyping was performed in patients with MS who experienced anaphylactic/anaphylactoid reactions and in patients who did not develop infusion-related allergic reactions following natalizumab administration.RESULTSA total of 119 patients with MS from 3 different cohorts were included in the study: 54 with natalizumab-related anaphylactic/anaphylactoid reactions and 65 without allergic reactions. HLA-DRB1*13 and HLA-DRB1*14 alleles were significantly increased in patients who developed anaphylactic/anaphylactoid reactions (p M-H = 3 × 10(-7); odds ratio [OR]M-H = 8.96, 95% confidence interval [CI] = 3.40-23.64), with a positive predictive value (PPV) of 82%. In contrast, the HLA-DRB1*15 allele was significantly more represented in patients who did not develop anaphylactic/anaphylactoid reactions to natalizumab (p M-H = 6 × 10(-4); ORM-H = 0.2, 95% CI = 0.08-0.50), with a PPV of 81%.CONCLUSIONSHLA-DRB1 genotyping before natalizumab treatment may help neurologists to identify patients with MS at risk for developing serious systemic hypersensitivity reactions associated with natalizumab administration.
PB Wolters Kluwer Health/LWW
PB American Academy of Neurology
YR 2014
FD 2014-12-11
LK http://hdl.handle.net/10668/2175
UL http://hdl.handle.net/10668/2175
LA en
NO de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, et al. Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. Neurol Neuroimmunol Neuroinflamm. 2014; 1(4):e47
NO Journal Article;
DS RISalud
RD Apr 5, 2025